Immunotherapy / PD-L1 inhibitorFDA-approvedSecond-line
Tecentriq
Generic name: atezolizumab
How it works
Blocks the PD-L1 receptor on cancer cells, allowing immune cells to recognize and attack them.
Cancer types
Lung Cancer— PD-L1-positive
Efficacy
In clinical trials, patients with non-small cell lung cancer who received Tecentriq had a response rate of approximately 23%.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Atezolizumab plus chemotherapy effective in Japanese patients with advanced lung cancer | Lung Cancer | observational | Twelve-month OS rates were 62.9% (atezo + CnP), 72.1% (atezo + PP), and 68.3% (atezo + bev + CP). | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Atezolizumab Monotherapy Window in Triple-Negative Breast Cancer | Breast Cancer | phase-2 | pCR rates in study arms A and B were similar (65.7% and 69.0%, respectively). | Source → |
| Cost-effectiveness of Atezolizumab for Lung Cancer Patients | Lung Cancer | phase-3 | Adding atezolizumab to chemotherapy increased QALYs by 0.721 at an incremental cost of NT$2,111,359. | Source → |
| Combining Two Treatments May Help Fight Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| Atezolizumab treatment may worsen eye problems in some lung cancer patients | Lung Cancer | observational | — | Source → |
| New Cancer Treatment Combination Shows Promise for Melanoma Patients | Melanoma | phase-2 | 12-month EFS was 72.0% (95%CI 57.9-89.5%), 12-month RFS was 73.3% (95%CI 56.9-94.5%), and 12-month DMFS 86.0% (95%CI 72.2-100%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.